3 transcripts
ABBV
Earnings call transcript
NYSE
2024 Q2
25 Jul 24
lymphoma after 2 or more lines of prior therapy. Epkinly is now the only T cell engaging bispecific approved in the U.S. to treat both follicular
ABBV
Earnings call transcript
NYSE
2023 Q4
2 Feb 24
epitope on T cells. Which has the potential to mitigate some of the adverse events associated with other T cell engaging BCMA-based therapies while
ABBV
Earnings call transcript
NYSE
2023 Q2
27 Jul 23
of this year. We plan to wait for these more mature data before engaging with regulatory agencies in order to have a more comprehensive picture
- Prev
- 1
- Next